Browse > Article
http://dx.doi.org/10.5230/jgc.2017.17.e16

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data  

Fuchs, Charles S. (Dana-Farber Cancer Institute)
Muro, Kei (Department of Clinical Oncology, Aichi Cancer Center Hospital)
Tomasek, Jiri (Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University)
Van Cutsem, Eric (University Hospital Gasthuisberg Leuven and KU Leuven)
Cho, Jae Yong (Gangnam Severance Hospital)
Oh, Sang-Cheul (Korea University Guro Hospital)
Safran, Howard (Oncology Research Group, Brown University)
Bodoky, Gyorgy (Szent Laszlo Hospita)
Chau, Ian (Royal Marsden Hospital, London and Surrey)
Shimada, Yasuhiro (Gastrointestinal Medical Oncology Division, National Cancer Center Hospital)
Al-Batran, Salah-Eddin (Institute of Clinical Research, Universitaren Centrum fur Tumorerkrankungen-University Cancer Center)
Passalacqua, Rodolfo (Istituti Ospitalieri di Cremona)
Ohtsu, Atsushi (Exploratory Oncology Research and Clinical Trial Center, National Cancer Center)
Emig, Michael (Lilly Deutschland GmbH)
Ferry, David (Eli Lilly and Company)
Chandrawansa, Kumari (Eli Lilly and Company)
Hsu, Yanzhi (Eli Lilly and Company)
Sashegyi, Andreas (Eli Lilly and Company)
Liepa, Astra M. (Eli Lilly and Company)
Wilke, Hansjochen (Departments of Oncology and Hematology with Integrated Palliative Care)
Publication Information
Journal of Gastric Cancer / v.17, no.2, 2017 , pp. 132-144 More about this Journal
Abstract
Purpose: To identify baseline prognostic factors for survival in patients with disease progression, during or after chemotherapy for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer. Materials and Methods: We pooled data from patients randomized between 2009 and 2012 in 2 phase III, global double-blind studies of ramucirumab for the treatment of advanced gastric or GEJ adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing therapy (REGARD and RAINBOW). Forty-one key baseline clinical and laboratory factors common in both studies were examined. Model building started with covariate screening using univariate Cox models (significance level=0.05). A stepwise multivariable Cox model identified the final prognostic factors (entry+exit significance level=0.01). Cox models were stratified by treatment and geographic region. The process was repeated to identify baseline prognostic quality of life (QoL) parameters. Results: Of 1,020 randomized patients, 953 (93%) patients without any missing covariates were included in the analysis. We identified 12 independent prognostic factors of poor survival: 1) peritoneal metastases; 2) Eastern Cooperative Oncology Group (ECOG) performance score 1; 3) the presence of a primary tumor; 4) time to progression since prior therapy <6 months; 5) poor/unknown tumor differentiation; abnormally low blood levels of 6) albumin, 7) sodium, and/or 8) lymphocytes; and abnormally high blood levels of 9) neutrophils, 10) aspartate aminotransferase (AST), 11) alkaline phosphatase (ALP), and/or 12) lactate dehydrogenase (LDH). Factors were used to devise a 4-tier prognostic index (median overall survival [OS] by risk [months]: high=3.4, moderate=6.4, medium=9.9, and low=14.5; Harrell's C-index=0.66; 95% confidence interval [CI], 0.64-0.68). Addition of QoL to the model identified patient-reported appetite loss as an independent prognostic factor. Conclusions: The identified prognostic factors and the reported prognostic index may help clinical decision-making, patient stratification, and planning of future clinical studies.
Keywords
Prognosis; Stomach neoplasms; Gastroesophageal junction; Survival;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.   DOI
2 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013 [cited 2015 Aug 1]. Available from: http://globocan.iarc.fr.
3 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al., eds. SEER Cancer Statistics Review, 1975-2012 (based on November 2014 SEER data submission, posted to the SEER web site, April 2015) [Internet]. Bethesda (MD): National Cancer Institute; 2015 [cited 2015 Aug 1]. Available from: http://seer.cancer.gov/csr/1975_2012/.
4 Avital I, Pisters PW, Kelsen DP, Willett CG. Cancer of the stomach. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2011;924-954.
5 Koh TJ, Wang TC. Tumors of the stomach. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. 7th ed. Philadelphia (PA): Saunders, 2002;829-844.
6 Layke JC, Lopez PP. Gastric cancer: diagnosis and treatment options. Am Fam Physician 2004;69:1133-1140.
7 Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-2403.   DOI
8 Chau I, Ashley S, Cunningham D. Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol 2009;27:e3-e4.   DOI
9 Koo DH, Ryoo BY, Kim HJ, Ryu MH, Lee SS, Moon JH, et al. A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemother Pharmacol 2011;68:913-921.   DOI
10 Takahari D, Boku N, Mizusawa J, Takashima A, Yamada Y, Yoshino T, et al. Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. Oncologist 2014;19:358-366.   DOI
11 Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008;99:1402-1407.   DOI
12 Kanagavel D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov MN, et al. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol 2010;21:1779-1785.   DOI
13 Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996;14:671-679.   DOI
14 Sun KY, Xu JB, Chen SL, Yuan YJ, Wu H, Peng JJ, et al. Novel immunological and nutritional-based prognostic index for gastric cancer. World J Gastroenterol 2015;21:5961-5971.   DOI
15 Dorcaratto D, Grande L, Ramon JM, Pera M. Quality of life of patients with cancer of the oesophagus and stomach. Cir Esp 2011;89:635-644.   DOI
16 Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-39.   DOI
17 Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-1235.   DOI
18 Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer, 2001.
19 Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.   DOI
20 Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.   DOI
21 Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-558.   DOI
22 Kusano T, Shiraishi N, Shiroshita H, Etoh T, Inomata M, Kitano S. Poor prognosis of advanced gastric cancer with metastatic suprapancreatic lymph nodes. Ann Surg Oncol 2013;20:2290-2295.   DOI
23 Louvet C, Carrat F, Mal F, Mabro M, Beerblock K, Vaillant JC, et al. Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Invest 2003;21:14-20.   DOI
24 Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994;30A:1263-1269.
25 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.   DOI
26 Watine J, Friedberg B, Bouarioua N. Biological variables and stratification of patients with inoperable non-small-cell bronchial cancer: recommendations for future trials. Cancer Radiother 2002;6:209-216.   DOI
27 Chen SL, Xue N, Wu MT, Chen H, He X, Li JP, et al. Influence of preoperative serum aspartate aminotransferase (AST) level on the prognosis of patients with non-small cell lung cancer. Int J Mol Sci 2016;17:1474-1486.   DOI
28 Zhang K, Lai Y, Axelrod R, Campling B, Hyslop T, Civan J, et al. Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests. Int J Cancer 2015;136:382-391.   DOI
29 Watine J, Friedberg B. Laboratory variables and stratification of metastatic colorectal cancer patients: recommendations for therapeutic trials and for clinical practice guidelines. Clin Chim Acta 2004;345:1-15.   DOI